RESUMEN
PURPOSE: To report outcome, complications and safety of retropupillary fixated iris-claw intraocular lenses in a pediatric population. DESIGN: Retrospective study. PATIENTS AND METHODS: Ten consecutive pediatric patients (15 eyes) underwent placement of retropupillary fixated iris-claw intraocular lenses between October 2007 and July 2013 at the Department of Ophthalmology, Medical University Graz and General Hospital Klagenfurt, Austria. Postoperative visual acuity and complications were analyzed. RESULTS: Median final best-corrected visual acuity improved by 0.12 logMAR from preoperative baseline. Mean postoperative spherical equivalent was -0.05 ± 1.76 D. No serious complications were observed intra- or postoperatively during the entire follow-up period of up to 40 months. One patient experienced a haptic disenclavation with IOL subluxation immediately after a car accident. CONCLUSION: Our study demonstrates that iris-claw intraocular lens implantation behind the iris is safe in children with lack of capsular support and yields excellent visual outcome with low complication rate.
Asunto(s)
Afaquia Poscatarata/cirugía , Implantación de Lentes Intraoculares/métodos , Lentes Intraoculares/efectos adversos , Adolescente , Afaquia Poscatarata/tratamiento farmacológico , Niño , Preescolar , Femenino , Humanos , Implantación de Lentes Intraoculares/efectos adversos , Masculino , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
OBJECTIVE: Polymorphisms of the vitamin D metabolism gene CYP27B1 showed associations with multiple autoimmune diseases. The aim of this study was to investigate a possible association between the rs703842 A>G polymorphism of the CYP27B1 gene and HLA-B27-associated uveitis. DESIGN: One hundred fifty-nine patients with HLA-B27-associated uveitis, 138 HLA-B27-negative controls and 100 HLA-B27-positive controls were recruited for this retrospective case-control study. Main outcome parameters were genotype distribution and allelic frequencies determined by polymerase chain reaction. RESULTS: Carriers of the rs703842G allele were found significantly more often in patients with HLA-B27-associated uveitis than in HLA-B27-positive controls (p = 0.03). Between patients and HLA-B27-negative controls no significant difference in the genotype distribution of the rs703842 A>G polymorphism was found (p = 0.97). CONCLUSIONS: Our data suggest that the rs703842 A>G polymorphism may play a role in HLA-B27-associated uveitis.
Asunto(s)
25-Hidroxivitamina D3 1-alfa-Hidroxilasa/genética , Estudios de Asociación Genética , Predisposición Genética a la Enfermedad , Antígeno HLA-B27/genética , Polimorfismo de Nucleótido Simple/genética , Uveítis/genética , Vitamina D/metabolismo , Adulto , Estudios de Casos y Controles , Demografía , Femenino , Humanos , Masculino , Uveítis/enzimología , Uveítis/inmunologíaRESUMEN
AIM: To evaluate visual quality and postoperative results as well adverse events in myopic patients undergoing I-CARE anterior-chamber angle-supported phakic intraocular lens (IOL) implantation. DESIGN: A retrospective, non-randomised, case series. PARTICIPANTS: Data on 29 eyes (16 patients) receiving I-CARE phakic IOL for high myopia (-11.66±3.3) were analysed. METHODS: The IOLs were implanted between 2003 and 2006 at the Department of Ophthalmology, Medical University, Graz, Austria. The mean follow-up was 51.7±16 months (17-78 months). MAIN OUTCOME MEASURES: The authors measured uncorrected visual acuity (UCVA) and best-corrected visual acuity (BCVA); patients underwent slit-lamp examination, corneal topography, Scheimpflug imaging and measurement of endothelial cells (EC). RESULTS: The mean UCVA and BCSVA were 0.63 and 0.94 decimal after 1 year. Endothelial cell loss was the most serious adverse event observed. The mean EC loss was 2%, 9%, 17%, 21%, 33% and 47% after 1 year (n=17), 2 years (n=20), 3 years (n=17), 4 years (n=17), 5 years (n=12) and 6 years (n=3), respectively. Eight IOL explantations were made due to severe EC loss 3-6 years after implantation. Other serious complications included one patient with Urrets-Zavalia Syndrome (one eye). CONCLUSION: Implantation of the I-CARE phakic-IOL is not a safe method for the correction of high myopia due to serious endothelial cell loss that might occur in a high number of patients. Patients with these IOLs should be followed up at least every 6 months, and the IOL should be explanted, once the EC count drops to less than 2000 cells/mm(2).